With 0.73 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.16 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.13 whereas the lowest price it dropped to was $1.08. The 52-week range on CTMX shows that it touched its highest point at $5.85 and its lowest point at $0.83 during that stretch. It currently has a 1-year price target of $5.29. Beta for the stock currently stands at 1.02.
Price Performance and Earnings:
The stock lost -30.67% in the past year, while it has gained 9.71% so far this year. A look at the trailing 12-month EPS for CTMX yields 0.17 with Next year EPS estimates of -0.43. For the next quarter, that number is -0.20. This implies an EPS growth rate of -328.04% for this year and -908.36% for next year. EPS is expected to decline by -0.90% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 67.21%.
Float and Shares Shorts:
At present, 78.23 million CTMX shares are outstanding with a float of 76.94 million shares on hand for trading. On 2024-12-13, short shares totaled 5.54 million, which was 708.0 higher than short shares on 1731628800. In addition to Dr. Sean A. McCarthy DPHIL as the firm’s Chairman & CEO, Dr. Marcia P. Belvin Ph.D. serves as its Senior VP & Chief Scientific Officer.
Institutional Ownership:
Through their ownership of 0.65668 of CTMX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, CTMX reported revenue of $33432000.0 and operating income of $4111000.0. The EBITDA in the recently reported quarter was $4540000.0 and diluted EPS was $0.07.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CTMX since 4 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CTMX analysts setting a high price target of 8.0 and a low target of 3.25, the average target price over the next 12 months is 5.286. Based on these targets, CTMX could surge 607.96% to reach the target high and rise by 187.61% to reach the target low. Reaching the average price target will result in a growth of 367.79% from current levels.
Analysts have provided yearly estimates in a range of $0.11985 being high and -$0.32531 being low. For CTMX, this leads to a yearly average estimate of -$0.042804.
